Adaptive Biotechnologies Corp

Biological Products, (No Diagnostic Substances)

ADPT Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001478320 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$3.86B
159,595,842 shares Covers every share class this company has on file.
Insiders on file
12
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$148.92M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
3.86%
insider-held value divided by market capitalisation

What Adaptive Biotechnologies Corp reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$276.98M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$59.50M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
624
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Adaptive Biotechnologies Corp

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Adaptive Biotechnologies Corp.
Insider Reported role Shares Value Last action
Officers 7
Harlan S. Robins Other Executive 1,522,058 $36.96M S Open-market sale Jul 21, 2026 position reported
Julie Rubinstein Julie Rubinstein COO 455,878 $11.07M S Open-market sale Apr 27, 2026 position reported
Susan Bobulsky Susan Bobulsky Other Executive 427,775 $10.39M S Open-market sale Aug 10, 2026 position reported
Francis Lo Francis Lo Other Executive 293,874 $7.14M S Open-market sale Jul 15, 2026 position reported
Sharon Benzeno Other Executive 272,751 $6.62M S Open-market sale Jun 29, 2026 position reported
Kyle Piskel Kyle Piskel CFO 259,840 $6.31M S Open-market sale May 18, 2026 position reported
Stacy L Taylor General Counsel 139,365 $3.38M position reported
Officers who also sit on the board 3
Chad M. Robins Chad M. Robins CEO 2,301,113 $55.87M S Open-market sale Aug 18, 2026 position reported
Peter M. Neupert Peter M. Neupert CEO 240,315 $5.83M S Open-market sale Aug 17, 2026 position reported
Robert Hershberg CEO 62,347 $1.51M S Open-market sale Aug 18, 2026 position reported
Directors 2
Katey Einterz Owen Board Member 88,254 $2.14M G Bona fide gift Aug 31, 2026 position reported
Michael J Pellini Board Member 69,690 $1.69M position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Harlan S. Robins sold 492,400 Adaptive Biotechnologies Corp (ADPT) shares for $10,780,409 on Jul 21, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Harlan S. Robins sold 492,400 Adaptive Biotechnologies Corp (ADPT) shares for $10,780,409 on Jul 21, 2026
Date Insider Transaction Shares Price Value Filing
Jul 21, 2026 Harlan S. Robins S Open-market sale 278,698 held after: 1,025,760 $21.72 $6,053,321 SEC filing ↗
Jul 21, 2026 Harlan S. Robins S Open-market sale 213,702 held after: 812,058 $22.12 $4,727,088 SEC filing ↗

Total of the rows above: $10,780,409, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Harlan S. Robins sold 492,400 Adaptive Biotechnologies Corp (ADPT) shares for $10,780,409 on Jul 21, 2026

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Harlan S. Robins sold 492,400 Adaptive Biotechnologies Corp (ADPT) shares for $10,780,409 on Jul 21, 2026
Date Insider Transaction Shares Price Value Filing
Jul 21, 2026 Harlan S. Robins S Open-market sale 278,698 held after: 1,025,760 $21.72 $6,053,321 SEC filing ↗
Jul 21, 2026 Harlan S. Robins S Open-market sale 213,702 held after: 812,058 $22.12 $4,727,088 SEC filing ↗

Total of the rows above: $10,780,409, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Harlan S. Robins sold 386,240 Adaptive Biotechnologies Corp (ADPT) shares for $8,501,149 on Jul 2, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Harlan S. Robins sold 386,240 Adaptive Biotechnologies Corp (ADPT) shares for $8,501,149 on Jul 2, 2026
Date Insider Transaction Shares Price Value Filing
Jul 2, 2026 Harlan S. Robins S Open-market sale 239,351 held after: 1,166,547 $21.74 $5,203,491 SEC filing ↗
Jul 2, 2026 Harlan S. Robins S Open-market sale 146,889 held after: 1,019,658 $22.45 $3,297,658 SEC filing ↗

Total of the rows above: $8,501,149, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Harlan S. Robins sold 386,240 Adaptive Biotechnologies Corp (ADPT) shares for $8,501,149 on Jul 2, 2026

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Harlan S. Robins sold 386,240 Adaptive Biotechnologies Corp (ADPT) shares for $8,501,149 on Jul 2, 2026
Date Insider Transaction Shares Price Value Filing
Jul 2, 2026 Harlan S. Robins S Open-market sale 239,351 held after: 1,166,547 $21.74 $5,203,491 SEC filing ↗
Jul 2, 2026 Harlan S. Robins S Open-market sale 146,889 held after: 1,019,658 $22.45 $3,297,658 SEC filing ↗

Total of the rows above: $8,501,149, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Sharon Benzeno sold 154,768 Adaptive Biotechnologies Corp (ADPT) shares for $3,271,796 on Jun 29, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Sharon Benzeno sold 154,768 Adaptive Biotechnologies Corp (ADPT) shares for $3,271,796 on Jun 29, 2026
Date Insider Transaction Shares Price Value Filing
Jun 29, 2026 Sharon Benzeno S Open-market sale 154,768 held after: 221,278 $21.14 $3,271,796 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Harlan S. Robins sold 329,600 Adaptive Biotechnologies Corp (ADPT) shares for $4,340,832 on Mar 11, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Harlan S. Robins sold 329,600 Adaptive Biotechnologies Corp (ADPT) shares for $4,340,832 on Mar 11, 2026
Date Insider Transaction Shares Price Value Filing
Mar 11, 2026 Harlan S. Robins S Open-market sale 329,600 held after: 1,522,058 $13.17 $4,340,832 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 289 rows we hold, 0 are open-market purchases and 149 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Adaptive Biotechnologies Corp, newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 31, 2026 Katey Einterz Owen G Bona fide gift 12,539 $0.00 $0 SEC filing ↗
Aug 26, 2026 Katey Einterz Owen S Open-market sale 9,615 $26.00 $250.0K SEC filing ↗
Aug 18, 2026 Robert Hershberg S Open-market sale 15,664 $24.41 $382.4K SEC filing ↗
Aug 18, 2026 Robert Hershberg S Open-market sale 15,000 $24.39 $365.9K SEC filing ↗
Aug 18, 2026 Robert Hershberg M Option exercise or conversion 15,000 $6.32 $94.8K SEC filing ↗
Aug 18, 2026 Chad M. Robins S Open-market sale 204 $25.14 $5.1K SEC filing ↗
Aug 18, 2026 Chad M. Robins S Open-market sale 278,472 $24.48 $6.82M SEC filing ↗
Aug 18, 2026 Chad M. Robins M Option exercise or conversion 278,676 $6.55 $1.83M SEC filing ↗
Aug 17, 2026 Chad M. Robins S Open-market sale 2,525 $25.57 $64.6K SEC filing ↗
Aug 17, 2026 Chad M. Robins S Open-market sale 318,799 $25.08 $8.00M SEC filing ↗
Aug 17, 2026 Chad M. Robins M Option exercise or conversion 321,324 $6.55 $2.10M SEC filing ↗
Aug 17, 2026 Peter M. Neupert S Open-market sale 69,690 $25.16 $1.75M SEC filing ↗
Aug 17, 2026 Peter M. Neupert S Open-market sale 40,000 $25.10 $1.00M SEC filing ↗
Aug 17, 2026 Peter M. Neupert S Open-market sale 15,000 $25.23 $378.5K SEC filing ↗
Aug 17, 2026 Peter M. Neupert M Option exercise or conversion 15,000 $6.32 $94.8K SEC filing ↗
Aug 10, 2026 Susan Bobulsky S Open-market sale 3,000 $25.00 $75.0K SEC filing ↗
Jul 30, 2026 Susan Bobulsky S Open-market sale 1,299 $24.00 $31.2K SEC filing ↗
Jul 21, 2026 Harlan S. Robins S Open-market sale 213,702 $22.12 $4.73M SEC filing ↗
Jul 21, 2026 Harlan S. Robins S Open-market sale 278,698 $21.72 $6.05M SEC filing ↗
Jul 21, 2026 Harlan S. Robins M Option exercise or conversion 284,800 $6.55 $1.87M SEC filing ↗
Jul 16, 2026 Susan Bobulsky S Open-market sale 5,000 $23.00 $115.0K SEC filing ↗
Jul 15, 2026 Francis Lo S Open-market sale 105,762 $22.59 $2.39M SEC filing ↗
Jul 15, 2026 Francis Lo M Option exercise or conversion 22,711 $8.46 $192.1K SEC filing ↗
Jul 15, 2026 Francis Lo M Option exercise or conversion 23,677 $12.14 $287.4K SEC filing ↗
Jul 15, 2026 Francis Lo M Option exercise or conversion 59,374 $7.80 $463.1K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Adaptive Biotechnologies Corp’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Adaptive Biotechnologies Corp’s own SEC filings multiplied by the closing price we hold for the same stock.